Nifty
Sensex
:
:
15940.90
53225.08
-299.40 (-1.84%)
-983.45 (-1.81%)

Pharmaceuticals & Drugs - Global

Rating :
47/99

BSE: 532523 | NSE: BIOCON

337.85
18-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  332.50
  •  347.10
  •  332.00
  •  330.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5155939
  •  17634.36
  •  420.25
  •  314.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 40,568.27
  • 62.67
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 42,911.47
  • 0.15%
  • 4.82

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.02%
  • 10.87%
  • FII
  • DII
  • Others
  • 15.62%
  • 8.32%
  • 3.53%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.79
  • 12.80
  • 8.82

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.55
  • 5.86
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.15
  • 6.59
  • -3.22

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 40.42
  • 63.20
  • 63.70

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.99
  • 6.05
  • 5.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.91
  • 26.61
  • 24.27

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
2,408.80
1,842.10
30.76%
2,174.20
1,857.40
17.06%
1,840.40
1,749.80
5.18%
1,760.60
1,693.80
3.94%
Expenses
1,816.90
1,406.40
29.19%
1,686.00
1,457.60
15.67%
1,394.60
1,358.40
2.66%
1,371.30
1,280.50
7.09%
EBITDA
591.90
435.70
35.85%
488.20
399.80
22.11%
445.80
391.40
13.90%
389.30
413.30
-5.81%
EBIDTM
24.57%
23.65%
22.45%
21.52%
24.22%
22.37%
22.11%
24.40%
Other Income
67.30
205.40
-67.23%
48.30
27.90
73.12%
104.90
15.50
576.77%
47.20
18.30
157.92%
Interest
10.50
33.90
-69.03%
14.70
4.80
206.25%
22.50
6.50
246.15%
19.90
12.50
59.20%
Depreciation
212.20
184.30
15.14%
205.70
186.30
10.41%
201.50
177.70
13.39%
194.80
166.80
16.79%
PBT
395.50
435.50
-9.18%
316.10
236.60
33.60%
256.60
222.70
15.22%
221.80
252.30
-12.09%
Tax
58.60
69.40
-15.56%
49.30
48.90
0.82%
46.30
22.30
107.62%
57.30
80.90
-29.17%
PAT
336.90
366.10
-7.98%
266.80
187.70
42.14%
210.30
200.40
4.94%
164.50
171.40
-4.03%
PATM
13.99%
19.87%
12.27%
10.11%
11.43%
11.45%
9.34%
10.12%
EPS
1.99
2.11
-5.69%
1.56
1.41
10.64%
1.15
1.41
-18.44%
0.70
1.25
-44.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
8,184.00
7,105.80
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,332.10
Net Sales Growth
14.57%
12.78%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
6.57%
 
Cost Of Goods Sold
2,718.40
2,208.50
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
Gross Profit
5,465.60
4,897.30
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,480.10
GP Margin
66.78%
68.92%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
63.47%
Total Expenditure
6,268.80
5,803.90
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
1,946.30
1,809.30
Power & Fuel Cost
-
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
% Of Sales
-
3.80%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.17%
Employee Cost
-
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
% Of Sales
-
24.50%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
13.19%
Manufacturing Exp.
-
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
113.20
% Of Sales
-
14.34%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
4.85%
General & Admin Exp.
-
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
% Of Sales
-
3.81%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.00%
Selling & Distn. Exp.
-
234.00
266.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
% Of Sales
-
3.29%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
3.83%
Miscellaneous Exp.
-
60.40
36.10
37.20
47.40
41.00
50.00
72.70
61.80
52.90
89.40
% Of Sales
-
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
2.13%
11.01%
EBITDA
1,915.20
1,301.90
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
539.00
522.80
EBITDA Margin
23.40%
18.32%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
21.69%
22.42%
Other Income
267.70
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
56.70
63.80
Interest
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
Depreciation
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
PBT
1,190.00
1,134.30
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
Tax
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
Tax Rate
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
PAT
978.50
819.70
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
PAT before Minority Interest
855.30
925.40
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
Minority Interest
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
PAT Margin
11.96%
11.54%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
14.65%
PAT Growth
5.72%
5.48%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
 
EPS
8.15
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45
4.24
2.85

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
Share Capital
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
2,491.80
2,079.80
Non-Current Liabilities
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
Secured Loans
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
Unsecured Loans
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
Long Term Provisions
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
Current Liabilities
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
Trade Payables
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
Other Current Liabilities
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
269.20
Short Term Borrowings
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
Short Term Provisions
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
Total Liabilities
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
Net Block
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
Gross Block
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
Accumulated Depreciation
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
Non Current Assets
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
Capital Work in Progress
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
Non Current Investment
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
Long Term Loans & Adv.
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
181.00
Other Non Current Assets
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
Current Assets
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
Current Investments
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
Inventories
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
Sundry Debtors
1,217.60
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
Cash & Bank
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
Other Current Assets
1,292.10
543.60
525.50
373.30
419.90
300.70
171.60
157.60
136.90
114.30
Short Term Loans & Adv.
286.90
265.60
153.10
54.70
24.10
134.70
75.80
81.80
81.40
37.10
Net Current Assets
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
Total Assets
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
PBT
846.20
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
395.20
Adjustment
931.10
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
144.80
Changes in Working Capital
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
Cash after chg. in Working capital
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
Net Fixed Assets
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
Net Investments
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
Others
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
Cash from Financing Activity
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
Net Cash Inflow / Outflow
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
Opening Cash & Equivalents
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
Closing Cash & Equivalent
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
21.59
18.16
ROA
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
ROE
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
21.50%
16.59%
ROCE
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
Fixed Asset Turnover
0.73
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.18
Receivable days
62.70
72.86
77.96
86.05
74.35
80.16
80.09
69.48
72.22
75.67
Inventory Days
84.82
71.47
58.05
60.00
54.81
53.71
48.47
48.54
56.01
60.69
Payable days
234.60
81.60
81.98
87.98
78.68
71.28
58.15
55.73
65.24
70.25
Cash Conversion Cycle
-87.08
62.74
54.04
58.07
50.48
62.59
70.42
62.29
62.99
66.11
Total Debt/Equity
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
0.10
0.12
Interest Cover
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13

News Update:


  • Biocon reports 19% fall in Q4 consolidated net profit
    29th Apr 2022, 11:19 AM

    The company has reported a standalone net profit of Rs 38.10 crore for the quarter ended March 31, 2022

    Read More
  • Biocon’s step down subsidiary bags contract from Malaysia to supply human insulin
    26th Apr 2022, 12:16 PM

    Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics

    Read More
  • Biocon’s arm inks pact to acquire Viatris’ biosimilars business
    28th Feb 2022, 09:17 AM

    Viatris will receive consideration of up to $3.335 billion, including cash up to $2.335 billion

    Read More
  • Biocon’s arm gets nod for Posaconazole Delayed-Release tablets from USFDA
    8th Feb 2022, 10:46 AM

    This approval further adds to Biocon’s portfolio of vertically integrated complex drug products

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.